Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLUL | P15104 | 1/20 | 0.40 |
| ▸ | GCLC | P48506 | 1/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058494 | 0.80 | GLUL (0.55) | GLULGCLCGRM8GRM6GRM7 | |
| SCHEMBL5054658 | 0.79 | PTGS1 (0.43) | GLULGCLCGRM8GRM6GRM7 | |
| SCHEMBL5072691 | 0.79 | GLUL (0.40) | GLULGCLCGRM8GRM6GRM7 | |
| SCHEMBL1980143 | 0.75 | GLUL (0.52) | GLULGCLC | |
| SCHEMBL195643 | 0.75 | GLUL (0.52) | GLULGCLC | |
| SCHEMBL8967238 | 0.75 | GLUL (0.52) | GLULGCLC | |
| SCHEMBL23649439 | 0.73 | GLUL (0.50) | GLULGCLC | |
| SCHEMBL28229605 | 0.73 | GLUL (0.50) | GLULGCLC | |
| SCHEMBL19697646 | 0.71 | PTGS1 (0.48) | GLULGCLC | |
| SCHEMBL13892954 | 0.71 | PTGS1 (0.48) | GLULGCLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | GLUL 1420/4885GCLC 2098/4885GRM8 2521/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | GLUL 1771/4885GCLC 2595/4885GRM8 1589/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | GLUL 1997/4885GCLC 2725/4885GRM8 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.